Travere Therapeutics (TVTX) Current Assets (2012 - 2026)

Travere Therapeutics has reported Current Assets for 15 years, with the latest figure at $392.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 4.95% year-over-year to $392.7 million; the trailing twelve-month figure through Mar 2026 stood at $392.7 million (up 4.95% YoY), and the FY2025 full-year result was $437.6 million, up 5.01% from the prior year.
• Current Assets for Q1 2026 stood at $392.7 million, down from $437.6 million in the prior quarter.
• The five-year high for Current Assets was $686.2 million in Q3 2023, with the low at $324.7 million in Q3 2024.
• Historically, Current Assets has averaged $484.5 million across 5 years, with a median of $481.1 million in 2024.
• Annual changes were most pronounced in 2023 — Current Assets rose 28.31% — and 2024, when it slumped 52.68%.
• Travere Therapeutics' Current Assets stood at $486.4 million in 2022, then rose by 26.79% to $616.8 million in 2023, then plunged by 32.44% to $416.7 million in 2024, then gained by 5.01% to $437.6 million in 2025, then retreated by 10.26% to $392.7 million in 2026.
• The last three Current Assets figures came in at $392.7 million (Q1 2026), $437.6 million (Q4 2025), and $371.1 million (Q3 2025), per Business Quant data.